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Abstract
Objective—To compare longitudinal adolescent and adult reproductive outcomes after pelvic 
inflammatory disease (PID).
Design—Secondary analysis of longitudinal data from the Pelvic Inflammatory Disease 
Evaluation and Clinical Health study.
Setting—A large multicenter randomized clinical trial assessing PID treatment strategies in the 
United States.
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Participants—Eight hundred thirty-one female patients aged 14 to 38 years with a diagnosis of 
PID.
Main Exposure—Adverse longitudinal outcomes were compared in adolescents (≤19 years) and 
adults (>19 years).
Outcome Measures—Primary outcome measures included recurrent sexually transmitted 
infection at 30 days, recurrent PID, chronic abdominal pain, infertility, pregnancy, and times to 
recurrent PID and pregnancy. Cox proportional hazards modeling was used to examine the effect 
of young age on times to pregnancy and recurrent PID.
Results—Adolescents were more likely than adults to have positive results of sexually 
transmitted infection testing at baseline and at 30 days. There were no significant group 
differences in chronic abdominal pain, infertility, and recurrent PID at 35 or 84 months, but 
adolescents were more likely to have a pregnancy at both time points. Adjusted hazard ratios (95% 
confidence intervals) also demonstrated that adolescents had shorter times to pregnancy (1.48 
[1.18–1.87]) and recurrent pelvic inflammatory disease (1.54 [1.03–2.30]).
Conclusion—Adolescents may require a different approach to clinical care and follow-up after 
PID to prevent recurrent sexually transmitted infections, recurrent PID, and unwanted 
pregnancies.
The Centers for Disease Control and Prevention (CDC) estimates that more than 1 million 
women are affected with pelvic inflammatory disease (PID) each year in the United States.1 
Adolescent girls are at risk for developing PID because of behavioral risk factors such as 
sexual concurrency2,3 and biological risk factors such as cervical ectopy that increase their 
risk of sexually transmitted infections (STIs).4 Adolescents are also at risk for the 
development of subsequent STIs after an initial episode of PID,5 and it is well established 
that recurrent STIs and/or PID increase the risk of associated reproductive health sequelae 
such as tubal infertility, ectopic pregnancy, and chronic abdominal pain.6 Optimal PID 
management requires that the affected patient engage in an effective but complicated 
regimen of self-treatment during a 14-day period. According to the treatment 
recommendations from the CDC, affected patients need twice-daily dosing with antibiotics 
to treat infection, to avoid reexposure to STIs during the treatment period, to assist in 
secondary prevention through partner notification and treatment, and to arrange for 
appropriate follow-up assessments. Research, however, has consistently demonstrated that 
adolescents and adult women with PID often have difficulty adhering to these 
recommendations.7–10 Given the risks to future fertility among women just entering their 
reproductive years, previous sexually transmitted disease treatment guidelines from the CDC 
have suggested that adolescents with PID should be considered separately in treatment 
recommendations. In the past, hospitalization was used to provide additional clinical care 
support to adolescents with PID. Although outpatient treatment was initially controversial,11 
hospitalization for PID is now usually reserved for those with severe manifestations of 
disease given the availability of effective oral antibiotic regimens. As a first step in 
determining the current need for more structured management of mild-to-moderate disease 
among adolescents in the outpatient setting, we compared longitudinal behavioral correlates 
and reproductive health outcomes between adolescents and adults with PID.
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We conducted a secondary analysis of data from the Pelvic Inflammatory Disease 
Evaluation and Clinical Health (PEACH) study, a large multicenter randomized clinical trial 
assessing PID treatment strategies. Although the methods used in this seminal trial have 
been well described in the literature,12,13 they will be briefly reviewed herein. Patients aged 
14 to 38 years with mild to moderate PID based on predetermined diagnostic criteria were 
enrolled at diagnosis at one of the 8 centers participating in the trial. The 3 required 
diagnostic criteria included (1) pelvic discomfort for fewer than 30 days, (2) pelvic organ 
tenderness on bimanual examination, and (3) leukorrhea, mucopurulent cervicitis, and/or 
known positive laboratory findings for Neisseria gonorrhoeae or Chlamydia trachomatis 
infection. Patients were excluded if they were identified as being at risk for acute morbidity 
in the outpatient setting (eg, pregnancy, inability to tolerate an outpatient regimen, tubo-
ovarian abscess, or a potential surgical abdomen); if they had pelvic pain for more than 30 
days, allergy to study drugs, antibiotic treatment within 7 days of recruitment, delivery or a 
gynecologic surgical procedure (including abortion) within the past 30 days, or a previous 
hysterectomy or salpingectomy; and if they were homeless.
Using these criteria, 1515 patients were eligible for participation in the study; of these, 651 
(43.0%) refused participation, and, among the remaining 864 who consented to participate, 
831 were randomly assigned to inpatient or outpatient antibiotic therapy (Figure 1). Refusal 
rates were similar to those of other studies that compared treatment strategies,14 and patients 
who refused to participate did not differ significantly by race, age, or clinical status. 
Perceived hardship for a potential hospitalization was noted as the primary reason for 
refusal.13 Parental consent was obtained for minors who participated in the trial.
Inpatient therapy included 48 hours of intravenous antibiotics on an inpatient unit with 
subsequent outpatient therapy with an oral antibiotic. Outpatient therapy included treatment 
with an oral antibiotic. All patients were advised to rest, notify partners of treatment, and 
abstain from sexual intercourse until both partners completed a course of treatment.
MEASURES
All participants completed a 20-minute baseline interview with reevaluation at 5 and 30 days 
from the time of enrollment and then a telephone interview every 3 to 4 months for 84 
months. Data collected at the baseline interview included demographic information, 
reproductive health history, lifestyle habits, and details of the current clinical illness. 
Patients also underwent a gynecologic examination with collection of biological specimens 
to test for N gonorrhoeae by culture and C trachomatis by polymerase chain reaction 
(Roche Medical Laboratories, Burlington, North Carolina) and an endometrial biopsy for 
detection of infection and determination of histology consistent with endometritis.
The primary outcomes of interest were recurrent STI at 30 days and recurrent PID, chronic 
pelvic pain, infertility, and pregnancy at 35 and 84 months. Each of the primary outcome 
variables was measured as yes or no and dichotomously coded (1 or 0). Time to pregnancy 
and recurrent PID were also measured. Recurrent PID was self-reported and verified 
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whenever medical records were available. As previously reported, confirmation of recurrent 
PID by self-reports and medical record reviews was similar.13 Infertility was defined when a 
sexually active patient with at least 12 months of follow-up did not report conception (a 
positive urine or blood test finding or a clinician’s diagnosis of pregnancy) despite rare or no 
use of contraceptive methods. Ectopic pregnancy was based on self-report, verified 
whenever possible by medical record review. Medical records were available for 45.0% of 
the cohort. Patients were considered to have chronic pelvic pain if pelvic pain was reported 
during at least 2 consecutive follow-up visits, thereby suggesting a minimum duration of 
pelvic pain of 6 months. Specific measures used in this analysis included demographic data, 
baseline reproductive health histories (ie, pregnancy history, PID history, evidence of 
endometritis at baseline, and level of distress if unable to have a child), sexual risk behavior 
(new sexual partners, number of partners in the past 4 weeks, contraceptive use in the past 4 
weeks, condom use by partner in the past 4 weeks, consistent condom use, and occasional 
condom use), adherence data (days between enrollment and follow-up, pill counts, 
intercourse during treatment window, and partner treatment), short-term treatment outcomes 
(STI [infection with N gonorrhoeae and/or C trachomatis] at 30 days after PID treatment 
and condom use at 30 days), and long-term treatment outcomes (recurrent PID and/or 
pregnancy at 35 and 84 months).
Other variables used to assess baseline differences between the age groups included age and 
race, health care access, insurance status, and regular access to health care (yes or no). Other 
baseline reproductive health history variables included ever having been pregnant (yes or 
no), live birth (yes or no), ectopic or tubal pregnancies (yes or no), miscarriages (yes or no), 
abortions (yes or no), cervical and/or endometrial N gonorrhoeae/C trachomatis infection at 
baseline (yes or no), baseline endometritis (yes or no), history of PID (yes or no), level of 
distress if the participant could not have a child (a 10-item scale recoded into 3 categories 
[0–3, 4–6, and 7–10]), mean days to follow-up, adherence to medication via pill counts (yes 
or no), sex during the treatment window (yes or no), and partner treatment after diagnosis 
(yes or no).
DATA ANALYSIS
Summary statistics by adolescents and adults were generated for each of the descriptive and 
primary outcome variables using commercially available software (SAS, version 9.2; SAS 
Institute, Inc, Cary, North Carolina). Adolescents were defined as participants aged 19 years 
or younger and adults were defined as participants older than 19. The parent study did not 
find differences between inpatient and outpatient treatment groups. However, before making 
comparisons across age groups, we conducted stratified within-group (adolescent and adult) 
analyses (not shown) to examine whether there were differences by intervention status 
(inpatient vs outpatient therapy) from the parent study.14 Baseline variables were then 
compared by age group strata. In all bivariate analyses, χ2 and unpaired t tests were used to 
evaluate differences for proportions and continuous variables, respectively. Times to 
recurrent PID and pregnancy were examined using Cox proportional hazards modeling 
adjusted for possible confounders, including history of pregnancy, history of PID, level of 
distress if the participant could not have additional children, consistent condom use, and 
treatment group.
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The original data collection was approved by the University of Pittsburgh institutional 
review board and each associated trial site. This analysis was approved by The Johns 
Hopkins University School of Medicine institutional review board.
RESULTS
SELECTED DEMOGRAPHICS
Adolescents represented 25.1% of the final sample size (Table 1). The mean (SD) ages for 
the adolescent and adult groups were 17.9 (1.1) and 25.3 (4.7) years, respectively. Except 
for the age differences, patients were demographically similar. Most were of African 
American descent, were of low-income status as measured by insurance status (uninsured/
public insurance), and reported regular access to health care. As previously reported, there 
were no significant differences between the inpatient and outpatient trial groups.13,15 Within 
age groups, adolescents and adults were also demographically similar regardless of 
randomization assignment.
REPRODUCTIVE HEALTH HISTORY AND RISK BEHAVIORS
Adolescents were less likely to have a history of pregnancy, live birth, abortion, or previous 
PID but were more likely to report higher levels of distress if unable to have a child. There 
were no significant differences in the numbers of new sexual partners or of partners in the 
past 4 weeks or contraceptive use in the past 4 weeks between the adolescents and adults. 
However, adolescents were more likely to report condom use by male partners within the 
past 4 weeks and to be engaging in consistent (10 of 10 times) condom use.
BASELINE AND LONGITUDINAL REPRODUCTIVE HEALTH OUTCOMES
There were no differences in the mean days to follow-up, adherence to medication via pill 
counts, sexual intercourse during the treatment window, or partner treatment after diagnosis 
(Table 2). However, adolescents were significantly more likely than adults to have evidence 
of endometritis and positive results of STI testing (N gonorrhoeae/C trachomatis infection) 
at baseline (63.2% vs 40.8%) (Table 1) and at 30 days (20.0% vs 5.2%) (Table 2).
As previously reported,15 at 35 months, 31.8% of participants had chronic abdominal pain, 
18.2% were categorized as infertile, 41.8% became pregnant, and 14.5% experienced 
recurrent PID. At 84 months, 42.7% of participants reported chronic abdominal pain, 18.6% 
were categorized as infertile, 57.2% became pregnant, and 21.3% had recurrent PID. There 
were no significant group differences in chronic abdominal pain, infertility, and recurrent 
PID at either time point, but adolescents were more likely to have a pregnancy at both time 
points (Table 3).
Graphical displays of the survival distribution against the times to pregnancy (Figure 2) and 
recurrent PID (Figure 3) show clear deviation between the 2 groups of study participants 
over time. Adjusted hazards models controlling for history of pregnancy, history of PID, 
level of distress if infertile, consistent condom use, and treatment group demonstrate that 
adolescents had shorter times to recurrent PID (hazard ratio, 1.54 [95% confidence interval, 
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1.03–2.30]; P = .03) and pregnancy (1.48 [1.18–1.87]; P <.001) compared with adult women 
(Table 4).
Two post hoc power analyses were conducted. The post hoc analysis for time to recurrent 
PID suggested 70% power for bivariate analyses, declining to 43% for the multivariable 
analysis with 5 confounders to detect a true hazard ratio of about 1.30. The post hoc analysis 
for time to recurrent pregnancy suggested greater than 80% power for bivariate and 
multivariate analyses to detect a true hazard ratio of about 1.60.
COMMENT
This study supports previous research by Weström and colleagues6 demonstrating that 
women experience significant reproductive health sequelae after a PID diagnosis.
During the 84-month study, 42.7% of patients in this US sample experienced chronic 
abdominal pain, 18.6% experienced infertility, and 21.3% had recurrent PID. Although 
adolescents reported more consistent condom use than adults at baseline and at follow-up, 
they were more likely to be infected with an STI at baseline and at 30 days and to have a 
shorter time to development of PID, further risking preservation of their reproductive 
function.
Although more than half the patients experienced a pregnancy, the rates of infertility among 
this mostly minority, low-income population of women were significant, particularly 
because these data derive from patients with the least severe symptoms (mild to moderate 
disease). The STI findings in adolescent girls appear counterintuitive given the reports of 
consistent condom use. These findings may reflect the highly contextual and evolving nature 
of condom use based on relationship status.16,17 Recent studies have suggested that reports 
of unprotected vs protected sexual intercourse do not correlate well with the presence of 
semen biomarkers in adult women.18 The social desirability bias that is likely driving this 
observation may be even greater when adolescents are questioned about sexual practices 
compared with adult women. Adult women are also more likely to be married or in a stable 
relationship, which may explain lower rates of condom use and STIs. Ultimately, these 
observations likely reflect the epidemiology of STIs among adolescents and young adults 
and the increased likelihood of encountering a partner with an STI over time.19 This analysis 
does not examine partner factors, but examination of relationship concurrency, disclosure, 
and partner treatment after each STI would be important factors to consider in future work.
Although adverse outcomes were similar by treatment arm in the entire cohort,15,20 our main 
goal was to determine whether, by comparing adolescent-specific outcomes with those of 
the adults, additional follow-up recommendations should be made to optimize outpatient 
care for adolescents facing a PID diagnosis. These data suggest that adolescents may be 
more likely to experience a pregnancy, have recurrent STIs, and have a shorter time to 
development of recurrent PID than adult women. The pregnancy finding is not surprising 
because previous studies have suggested that girls who perceive an impairment of their 
fertility are less likely to use contraception,21 that few adolescents diagnosed as having PID 
in observational trials are using contraception,10 and that adolescents often believe that 
prevention of infertility is beyond their control.22 These data, combined with our earlier 
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work demonstrating the disparities in health care delivery for PID in pediatric ambulatory 
settings, the difficulty with adherence faced by many adolescents,8,10 and recurrent rates of 
STIs and PID after a diagnosis of PID,5 suggest that health service delivery should be 
expanded for prevention of recurrent STIs, PID, and teen pregnancy through risk reduction 
interventions.
The findings from this study must be considered in light of several general limitations. The 
sample primarily consisted of low-income African American women and may not be 
generalizable to other patients in other settings. However, research in this population is 
important given the documented racial/ethnic health disparities associated with STIs, PID,23 
and infertility in the United States.23–26 There is limited variability of the adolescent cohort 
because this sample primarily consists of older adolescents and young adults as indicated by 
the mean (SD) age of the adolescent sample. Younger adolescents and/or adolescents who 
refused to participate because they were seeking confidential services may have differed 
systematically from participants in ways that could have resulted in more negative PID 
outcomes. The adolescents in this sample were, however, clearly different in behavior and 
outcome than the adult sample; thus, the stratification and findings from this work are still 
important. Although the study findings suggest high adherence to medication regimens, the 
measure of adherence for most patients in the study was limited to pill counts performed at 
clinic visits. Thus, differences in adherence between adolescents and adults may exist, but 
we are unable to determine them based on available data. Given that this was a randomized 
controlled trial, it is possible that the participants in the study were dissimilar to patients in 
reality settings. As an example, previous studies have demonstrated very low contraceptive 
use rates among adolescents with PID,10,27 but more than 70% of the participants in both 
groups reported using some form of contraception. This might suggest a slightly lower risk 
profile for women in this sample. However, the PEACH study represents the most 
comprehensive longitudinal data with US women affected by PID and has provided 
excellent efficacy data on outpatient treatment under the best possible conditions and should 
be used as a template for translational work that establishes the effectiveness of outpatient 
treatment approaches among the high-risk populations often affected by PID.
The CDC has been clear in that health care providers working with adolescents diagnosed as 
having PID should engage in careful, developmentally appropriate, and non-judgmental 
discussions aimed at reduction of high-risk behaviors in adolescents.28 The findings from 
this research suggest that, although adolescent-specific PID management needs to include 
more aggressive risk reduction interventions to prevent subsequent STIs, PID, and teen 
pregnancy after a PID diagnosis, a reduction in PID-associated chronic abdominal pain and 
infertility among all women is also needed.
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Approach to analysis in the context of the Pelvic Inflammatory Disease Evaluation and 
Clinical Health (PEACH) study design. PID indicates pelvic inflammatory disease.
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Survival curves depicting time to pregnancy by age group status (adults >19 years and 
adolescents ≤19 years). Circles indicate censored individuals.
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Survival curve depicting time to recurrent pelvic inflammatory disease (PID) by age group 
status (adults >19 years and adolescents ≤19 years). Circles indicate censored individuals.
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Table 1
Selected Baseline Demographics, Reproductive Health History/Status, and Reported Risk Behaviors by Group 
Statusa
Characteristic Adolescents (n=209) Adults (n=622) P Value
Demographics
 Age, mean (SD), y 17.9 (1.1) 25.3 (4.7) <.001
 Race
  African American 158 (75.6) 463 (74.4)
.54
  White 32 (15.3) 101 (16.2)
  Hispanic 10 (4.8) 41 (6.6)
  Native American/Alaskan native/Asian 9 (4.3) 17 (2.7)
Health care access and insurance status
 Health care insurance 101 (54.9) 292 (51.0) .35
 Regular access to health care 124 (67.4) 415 (72.4) .19
 Insurance status
  Uninsured 83 (45.1) 281 (49.0)
.44  Private insurance 33 (17.9) 82 (14.3)
  Public insurance 68 (37.0) 210 (36.6)
Reproductive health history/status
 Ever been pregnant 109/209 (52.2) 516/618 (83.5) <.001
 Live births 83/209 (39.7) 453/618 (73.3) <.001
 Ectopic pregnancies 3/209 (1.4) 36/617 (5.8) .01
 Miscarriages 34/209 (16.3) 164/618 (26.5) .003
 Abortions 29/209 (13.9) 172/618 (27.8) <.001
Positive cervical and/or endometrial Neisseria gonorrhoeae/Chlamydia 
trachomatis
110/174 (63.2) 195/477 (40.8) <.001
Evidence of endometritis 92/164 (56.1) 219/490 (44.7) .01
History of pelvic inflammatory disease 52/207 (25.1) 199/615 (32.4) .051
Level of distress if you could not have a child
 0–3 16 (15.5) 93 (32.3)
.004 4–6 13 (12.6) 35 (12.2)
 7–10 74 (71.8) 160 (55.6)
Sexual risk behavior
 New sexual partner 26 (12.4) 52 (8.4) .08
 No. of sexual partners in past 4 wk, mean (SD) 1.3 (3.9) 1.0 (1.2) .33
 Any contraceptive use in past 4 wk 131/175 (74.9) 377/528 (71.4) .38
 Any condom use by male partner in past 4 wk 112/176 (63.6) 259/528 (49.1) <.001
 Consistent condom use (10 of 10 sexual encounters) 34/176 (19.3) 59/528 (11.2) .006
aUnless otherwise indicated, data are expressed as number (percentage) of participants. Percentages have been rounded and may not total 100. 
Adolescents are aged 19 years or younger; adults, older than 19 years.
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Table 2
Patient Adherence and Short-term Outcomes by Group Statusa
Adherence Measure Adolescents (n=209) Adults (n=622) P Value
Time from enrollment to first follow-up, mean (SD), d 6.2 (3.5) 6.2 (3.3) .87
Pills (2 tablets/14 visits)
 Total No. of pills taken, mean (SD) 27.6 (1.7) 27.5 (2.5)
 Median 28.0 28.0 .25
Adherence, %
 Mean (SD) 98.7 (6.1) 98.2 (8.9)
 Median 100.0 100.0 .25
Sex during treatment window 28/184 (15.2) 84/571 (14.7) .85
Partner treatment after PID diagnosis 42/140 (29.8) 137/469 (29.2) .88
Cervical and/or endometrial Neisseria gonorrhoeae/Chlamydia trachomatis at 30 d 
after treatment
19/95 (20.0) 13/250 (5.2) <.001
Self-report of patient/partner STI since diagnosis 60/144 (41.7) 175/442 (39.6) .66
Condom use at 30 d 123/138 (89.1) 281/387 (72.6) <.001
Abbreviations: PID, pelvic inflammatory disease; STI, sexually transmitted infection.
aUnless otherwise indicated, data are expressed as number (percentage) of participants. Adolescents are aged 19 years or younger; adults, older 
than 19 years.
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Table 3
Adverse Reproductive Health Outcomes After PID at 35 and 84 Months and Time to Pregnancy and Recurrent 
PIDa
Outcomes Adolescents Adults P Value
At 35 mo
 Chronic pelvic pain 58/192 (30.2) 180/557 (32.3) .55
 Infertility 34/193 (17.6) 104/567 (18.3) .82
 Pregnancy 109/207 (52.7) 229/601 (38.1) .003
 Recurrent PID 36/207 (17.4) 81/601 (13.5) .17
At 84 mo
 Chronic pelvic pain 82/204 (40.2) 259/595 (43.5) .41
 Infertility 36/207 (17.4) 116/610 (19) .60
 Pregnancy 149/207 (72.0) 321/610 (52.6) <.001
 Recurrent PID 50/199 (25.1) 118/590 (20.3) .13
Time to event, mean (SD), mo
  Pregnancy 33.0 (26.6) 39.8 (28.9) .003
  Recurrent PID 50.4 (29.4) 52.0 (29.3) .52
Abbreviation: PID, pelvic inflammatory disease.
aUnless otherwise indicated, data are expressed as number (percentage) of participants. Adolescents are aged 19 years or younger; adults, older 
than 19 years.
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Table 4
Effect of Adolescent Age on Time to Pregnancy and Recurrent PID
HR (95% CI)
P ValueUnadjusted Adjusteda
Time to recurrent PID 1.28 (0.92–1.79) 1.54 (1.03–2.30) .03
Time to pregnancy 1.59 (1.31–1.93) 1.48 (1.18–1.87) <.001
Abbreviations: CI, confidence interval; HR, hazard ratio; PID, pelvic inflammatory disease.
aAdjusted for history of pregnancy, history of PID, level of distress if the participant could not have additional children, consistent condom use, 
and treatment group.
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